The role of glatiramer acetate in the early treatment of multiple sclerosis
David W BrandesHope MS Center, Knoxville, TN, USA; ULCA, Los Angeles, CA, USAAbstract: The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatm...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-06-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Online Access: | http://www.dovepress.com/the-role-of-glatiramer-acetate-in-the-early-treatment-of-multiple-scle-a4565 |